Finnish drug development company Herantis Pharma plc (HEL:
HRTIS) has advanced to the final patient cohort in its Lymfactin study and announced initial plans for continued development, the company reported on Thursday.
Herantis Pharma plc (HEL:
HRTIS) has received authorisation from the Medicines Agency of Sweden, MPA, to begin its first-in-human clinical study of its investigational product CDNF for the treatment of Parkinson's disease, the company disclosed on Thursday.
Finnish Medicines Agency Fimea has authorised Herantis Pharma plc's (HEL:
HRTIS) first-in-human clinical study of its investigational product CDNF for the treatment of Parkinson's disease, the Finnish drug development company reported on Monday.